Supreme Court Gets Final Say on Overtime
With conflicting lower court decisions over whether pharmaceutical sales reps should be paid for overtime, the Supreme Court has agreed to settle the matter. The court will hear the case brought by two former GSK reps that were denied their overtime claim by a Circuit Court.
With conflicting lower court decisions over whether pharmaceutical sales reps should be paid for overtime, the Supreme Court has agreed to settle the matter. The court will hear the case brought by two former GSK reps that were denied their overtime claim by a Circuit Court.
For years the industry has warned that overtime suits may swamp the industry with potentially billions of retroactive payments.
The biggest challenge for the Court will be to untangle conflicting stances from the various circuit courts. Last year a lower court decisions granted overtime payments to sales representatives at Novartis and Merck, finding that sales reps at Novartis and Schering Plough (now Merck) did not qualify for the "sales" exemption and were in fact owed overtime pay.
In the suit reps claimed that their primary responsibility was to visit physicians' offices, drop off drug samples, and deliver scripted messages about the company's products. Echoing the opinion of much of the pharmaceutical industry, the company argued that these workers are outside salespersons and therefore exempt from overtime pay under federal and state law.
Interestingly, The Department of Justice has argued along with the reps, that the employees were not eligible for an "outside sales exemption" and, in fact, were not engaged in sales activities.
A decision is not expected until June 2012.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
